主管单位:中华人民共和国
国家卫生健康委员会
主办单位:中国医师协会
总编辑:杨秋
编辑部主任:吴翔宇
邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)
英文作者:Zhou Xinrui Shen Qing
英文单位:Department of Nephropathy the First Affiliated Hospital of Chongqing Medical University Chongqing 400016 China
英文关键词:Continuousrenalreplacementtherapy;Nafamostat;Anticoagulant
连续性肾脏替代治疗(CRRT)是一种广泛应用的体外循环血液净化技术,体外循环回路凝血是其常见并发症之一。临床上常使用肝素作为循环抗凝剂,但较高的出血风险使得该方案并不适用于凝血功能异常的患者。萘莫司他抗凝作用强,出血风险较小,更适合应用于具有高出血风险的患者。本文对萘莫司他在CRRT中的临床研究进展进行综述,以期能够为CRRT抗凝剂的选择提供一定的参考价值。
Continuous renal replacement therapy (CRRT) is a widely used blood purification technique in extracorporeal circulation, and coagulation in the extracorporeal circulation circuit is one of its common complications. Heparin is commonly used as a circulating anticoagulant in clinical practice, but the higher risk of bleeding makes this regimen not suitable for patients with abnormal coagulation function. Nafamostat has a strong anticoagulant effect and a low risk of bleeding, which is more suitable for patients with high bleeding risk. This article reviews the clinical research progress of nafamostat in CRRT, in order to provide some reference value for the selection of anticoagulants for CRRT.
copyright 《中国医药》杂志编辑部
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址:www.chinamedicinej.com 京ICP备2020043099号-3
当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。